Products for Research Use Only

Sonelokimab

CAT: 0804-HY-P99397-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99397-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis[1][2][3][4].
CAS Number
1414386-05-2
Product Name Alternative
ALX 0761; M 1095
UNSPSC
12352203
Target
Interleukin Related; MMP
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sonelokimab.html
Purity
99.81
Solubility
H2O
Smiles
[Sonelokimab]
Molecular Weight
(40.11 kDa)
References & Citations
[1]Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25 (7) :751-4. |[2]Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289 (14) :4304-4327. |[3]Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977.|[4]Vanheusden K, et al. Pre-clinical proof-of-concept of ALX-0761, a Nanobody® neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model[C]//ARTHRITIS AND RHEUMATISM. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: Wiley-Blackwell, 2013, 65: S543-S543.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-17